Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Sarcoma 8Neoplasms 4Neoplasm Metastasis 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Docetaxel 158Prednisone 131Leuprolide 95bicalutamide 86enzalutamide 83Radiotherapy 80Goserelin 80Abiraterone Acetate 76acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 54Magnetic Resonance Spectroscopy 46Zoledronic Acid 44gallium 68 PSMA-11 37Flutamide 34abiraterone 32Estramustine 32radium Ra 223 dichloride 30apalutamide 27Surveys and Questionnaires 26Gonadotropin-Releasing Hormone 26Androgen Antagonists 25cabazitaxel 24Radiosurgery 24Dutasteride 22sipuleucel-T 21Prednisolone 21Triptorelin Pamoate 20Paclitaxel 20luprolide acetate gel depot 19Radiation 19Exercise 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Prostatic Neoplasms × olaratumab × Clear all
NCT01204710 2019-09-20

A Study of Olaratumab (IMC-3G3) in Prostate Cancer

Eli Lilly and Company

Phase 2 Completed
123 enrolled 21 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡